Evidence map›Paper›PMID 41982727›Full record

ArticleACS medicinal chemistry letters2026

Design, Synthesis and Biological Evaluation of Oxadiazole-Biphenyl Derivatives as Small Molecule Inhibitors Targeting PD-1/PD-L1 Immune Checkpoint.

Lingfeng Xie, Mingxuan Zhu, Tong Zhao, Yifeng Pei, Bo Wei, Shilong Zhu, Jiaoru Chen, Huibin Zhang, Jinpei Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lingfeng XieDepartment of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, P. R. China.
Mingxuan ZhuCenter of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, P. R. China.
Tong ZhaoDepartment of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, P. R. China.
Yifeng PeiCenter of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, P. R. China.
Bo WeiDepartment of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, P. R. China.
Shilong ZhuCenter of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, P. R. China.
Jiaoru ChenCenter of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, P. R. China.
Huibin ZhangCenter of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, P. R. China.ORCID https://orcid.org/0000-0001-8600-7737
Jinpei ZhouDepartment of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, P. R. China.ORCID https://orcid.org/0000-0002-5904-6164

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) targeting programmed cell death protein-1 and its ligand 1 (PD-1/PD-L1) have demonstrated significant efficacy in cancer immunotherapy. However, mAbs still have limitations in pharmacokinetic properties and immunogenicity. As a complementary approach, PD-1/PD-L1 small molecule inhibitors have thus become an attractive direction for development. In this study, a series of novel small molecule compounds based on an oxadiazole-biphenyl scaffold were designed and synthesized. Biological evaluation showed that compound

Indexed as

cancer immunotherapyimmune checkpoint blockadePD-1/PD-L1small molecular inhibitors

Identifiers

PMID41982727
PMCPMC13071646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.